FindTrial
Sign In

Phase III clinical study in patients with chronic pain

Confirmatory study of HFT-290 in patients with chronic pain

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221563
Enrollment
Unknown
Registered
2011-09-06
Start date
2011-09-06
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic pain

Interventions

investigational material(s) Generic name etc : HFT-290 (fentanyl citrate patch) INN of investigational material : Therapeutic category code : 821 Synthetic narcotics Dosage and Administration for Inv

Sponsors

Hisamitsu Pharmaceutical Co., Inc.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Patients with persistent chronic pain for 12 weeks or longer before obtaining informed consent.

Exclusion criteria

Exclusion criteria: - Patients with abnormalities at the application site. - Patient with serious cardiac, hepatic, or renal dysfunction, serious respiratory disorders, serious respiratory depression, and other serious complications. - Patients undergoing elective surgery that may have an effect on evaluation of pain.

Design outcomes

Primary

MeasureTime frame
Efficacy, safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026